Engineered ligand‐based VEGFR antagonists with increased receptor binding affinity more effectively inhibit angiogenesis

Pathologic angiogenesis is mediated by the coordinated action of the vascular endothelial growth factor (VEGF)/vascular endothelial growth factor receptor 2 (VEGFR2) signaling axis, along with crosstalk contributed by other receptors, notably α(v)β(3) integrin. We build on earlier work demonstrating...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Bioeng Transl Med
Egile Nagusiak: Kapur, Shiven, Silverman, Adam P., Ye, Anne Z., Papo, Niv, Jindal, Darren, Blumenkranz, Mark S., Cochran, Jennifer R.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2017
Gaiak:
Research Reports
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5412928/
https://ncbi.nlm.nih.gov/pubmed/28516164
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/btm2.10051
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak